USPH · U S Physical Therapy Inc /Nv
$83.96
+0.24 (+0.29%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$1.27B
Shares
14.92M
Volume · Oct 5
193.53K
Avg daily vol (3M)
205.68K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$83.72
Open$83.21
Day$82.55–84.69
52W close$59.00–93.16
Avg vol 30d172K
Short int1.3M · 8.7% float · 8.1d
Short vol62%
Last earningsAug 6, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 7
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 4 wks
filed Aug 7, 2026
call held May 7, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$812.20M
Trailing 12 months
Net income (TTM)
$32.23M
Trailing 12 months
Revenue growth YoY
+8.5%
Year over year
Operating margin
9.4%
Trailing 12 months
P / E (TTM)
492.5
Trailing earnings · reciprocal yield 0.2%
FCF yield
5.1%
TTM · current market cap
Return on invested capital
8.8%
Trailing 12 months
Net cash
−$195.13M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-0.8%
Year over year · fewer shares
Price change (1Y)
-4.0%
Trailing year
Short interest
8.7%
Latest settlement · 8.1 days to cover
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Moderate
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+10%
above
Price vs 50-day avg
+4%
above
RSI (14)
57
neutral
MACD trend
Positive
52-week position
72%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+6%
trailing
6-month return
+7%
trailing
YTD return
+7%
this year
Relative strength
−5%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $80 › 200d $76 — 50d above 200d
Institutional flow
Distributing
-4% holders QoQ · +28 funds added
Insider flow
Accumulating
Net +$395 over 90 days · 0% sells
Short interest
Rising
8.67% of float · ▲ +0.7% MoM · 8.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
219 holders — near 3-yr low, contrarian setup
Squeeze score
78
high risk · 0–100
Fundamentals
Revenue growth
+16%
Y/Y
Gross margin
19%
expanding
EPS growth
−23%
Y/Y
Buyback
$25.0M
authorized
Balance sheet
$126.9M
net debt
Quant / Vol
risk profile
Volatility
39%
annualized · 1-yr
Max drawdown
−37%
past year
ATR
2.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
Adjusted EBITDA
· full year 2026
Non-GAAP
Initiated
$102M – $106M
Guided vs delivered
· last 1 settled
Operating results per diluted share
full year 2021
guided $3.05 – $3.15
$2.41
Miss −22.3%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+10%
Bullish
Price vs 50-day avg
+4%
Bullish
RSI (14)
57
Neutral
MACD trend
Positive
Bullish
52-week position
72%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $80 › 200d $76 — 50d above 200d
Institutional flow
Distributing
-4% holders QoQ · +28 funds added
Insider flow
Accumulating
Net +$395 over 90 days · 0% sells
Short interest
Rising
8.67% of float · ▲ +0.7% MoM · 8.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
219 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $59
Now $84 · 72%
Range high $93
vs 200-day avg +10%
vs 50-day avg +4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Average Visits Per Day | 33.5 | Second quarter 2026 filing | — |
| Effective interest rate | 5.3% | Three Months Ended June 30, 2026 filing | — |
| Effective interest rate on Senior Credit Facilities | 5.3% | the three months ended June 30, 2026 filing | — |
| Visits | 1,661,694 | Second quarter 2026 filing | — |
| Adjusted EBITDA (a non-GAAP measure) non-GAAP | $47.2M | Six Months Ended June 30, 2026 | — |
| Adjusted physical therapy operations gross profit margin non-GAAP | 18.1% | Six Months Ended June 30, 2026 | — |
| Adjusted salaries and related costs, as a percentage of revenue non-GAAP | 58.6% | Six Months Ended June 30, 2026 | — |
| Average daily visits per clinic | 32.7 | Six Months Ended June 30, 2026 | — |
| IIP gross profit margin | 20.4% | Six Months Ended June 30, 2026 | — |
| Mature revenue percent change | 3.1% | Six Months Ended June 30, 2026 | — |
| Number of clinics, end of period | 781 | Q2 2026 | — |
|
|
|||
| Operating Results (a non-GAAP measure) non-GAAP | $18.23M | Six Months Ended June 30, 2026 | — |
| Operating Results per share (a non-GAAP measure) non-GAAP | $1.21 | Six Months Ended June 30, 2026 | — |
| Patient visits | 3,204,838 | Six Months Ended June 30, 2026 | — |
| Physical therapy operations gross profit margin | 19.5% | Q2 2026 | — |
| Physical therapy revenue per patient visit | $107.06 | Six Months Ended June 30, 2026 | — |
| Salaries and related costs, as a percentage of revenue | 58.9% | Six Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
USPH
this stock
U S Physical Therapy Inc /Nv
|
$1.27B | +7.2% | +16.3% | — | 8.7% |
|
HCA
HCA Healthcare, Inc.
|
$96.64B | -8.6% | +7.1% | 15.0 | 2.9% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$29.92B | -13.3% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$20.91B | +30.1% | +0.9% | 10.0 | 2.5% |
|
EHC
Encompass Health Corp
|
$12.18B | +12.9% | +10.5% | 20.1 | 3.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| USPH | -1.3% | +6.5% | +6.9% | -2.3% | +7.2% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -1.1% | +6.9% | -5.3% | -3.3% | -5.7% |
Capital returns
Buyback program
· as of Aug 10, 2026
Authorized
$25.00M
Spent (derived)
—
Remaining
—
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.